← All trials
NCT06179537
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 6, 2021
- Primary completion
- Oct 22, 2021
- Completion date
- Nov 21, 2021
- First posted
- Dec 22, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 34
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.